Gilead Sciences Inc

Dow Jones

Dow Jones Today Falls 80 Points as Fed FOMC Meeting Looms

The Dow Jones today traded 80 points lower in pre-market trading as the Federal Reserve kicked off its quarterly Federal Open Market Committee meeting.

Markets anticipate that the Fed will hold off on raising interest rates until June.

While interest rates are likely to remain unchanged, investors are paying close attention to any changes in the rhetoric used to describe the state of the American economy.



My Top Biotech Play for 2018 Could Make You 110.5% in 12 Months, If You Act Now

Between Oct. 5 and Nov. 11, one of the bellwether biotech exchange-traded funds fell 10.5%.

That's a correction, as defined by most market watchers.

And most investors – and their "enablers" on Wall Street – have shied away from biotech shares since. They're jittery.

In fact, I saw one august financial publication – the highly respected Investor's Business Daily – warn folks away from biotech in 2018 due to "median tenure of chief executives at large-cap biotech companies."

That's not just a stretch. It's a load of malarkey.

Here's the thing: If you want to double your money in 2018, you absolutely must invest in biotech.

That temporary dip in the iShares Nasdaq Biotechnology Index Fund ETF came after congressional Republicans ditched efforts to repeal and replace Obamacare. If there's one thing Wall Street hates, it's uncertainty.

As you might expect, Wall Street's panic led it to ignore some shares that have very bright futures – and are now trading at huge discounts.

So I've crunched the numbers – and done the research – and have identified three beaten-down biotech leaders that are poised to make huge comebacks throughout 2018.

I think you should put all three of these 2018 biotech comeback stocks on your "buy" list.

Especially the one that I believe will soar 110.5% in just 12 months...


Three Biotech Bargains to Buy Right Now

Back in October, I did something crazy.

That's when I told the paid-up members of my Radical Technology Profits trading service to buy a small-cap biotech stock.

Here's why that move was a bit nuts.

At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.

Turns out, however, our crazy bet paid off.

Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.

That helped pushed biotech and drug stocks into a big uptrend.

And my paid-up members made peak gains of 116% – in just over eight months.

Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.

But to do that, you have to know how to find those deals.

I do.

Today I'll show you how you can, too.

And I'll reveal the three best biotech bargains out there right now.

All three have triple-digit gains potential...


If You Own Just One Pharma Stock, Make It This

As I've said before, buying a drugmaker with true billion-dollar "blockbuster" potential is like grabbing a license to print money.

Of course, it's always at least possible to grab these shares on their way up, but that's a little like fixing the barn door after the horses have bolted.

For the biggest possible pharma profits, investors have to look ahead into the firm's "pipeline," its arsenal of yet-to-be-released drugs that's critical to keeping a drug company competitive in the long term.

Today, I've got the perfect "Buy" recommendation for a company that's doing just that...